Byrne Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Byrne Asset Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$13.7K	Hold	22	–	–	0.01%	398
2026 Q1	$17K	Sell	22 -1	-4%	-$766	0.01%	357
2025 Q4	$17.8K	Buy	23 +1	+5%	+$679	0.01%	362
2025 Q3	$12.4K	Sell	22 -5	-19%	-$2.83K	0.01%	393
2025 Q2	$14.2K	Hold	27	–	–	0.01%	369
2025 Q1	$17.1K	Buy	+27	New	+$18.6K	0.01%	355
2024 Q4	–	Sell	-41	Closed	-$34.4K	–	262
2024 Q3	$43.1K	Hold	41	–	–	0.03%	215
2024 Q2	$43.1K	Hold	41	–	–	0.03%	217
2024 Q1	$39.5K	Hold	41	–	–	0.03%	221
2023 Q4	$35.8K	Hold	41	–	–	0.03%	221
2023 Q3	$34K	Hold	41	–	–	0.03%	222
2023 Q2	$29K	Hold	41	–	–	0.02%	287
2023 Q1	$34K	Hold	41	–	–	0.02%	257
2022 Q4	$29.6K	Sell	41 -7	-15%	-$5.17K	0.02%	280
2022 Q3	$33K	Hold	48	–	–	0.03%	238
2022 Q2	$28K	Hold	48	–	–	0.02%	238
2022 Q1	$34K	Sell	48 -6	-11%	-$3.8K	0.02%	252
2021 Q4	$34K	Buy	+54	New	+$33.2K	0.02%	244

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Byrne Asset Management's REGN Position: Q2 2026 in Review

Byrne Asset Management held its Regeneron Pharmaceuticals (REGN) position steady in Q2 2026 at 22 shares worth $13.7K. The position accounts for 0.01% of the portfolio, ranked #398.

Byrne Asset Management first reported a position in REGN in Q4 2021 and has held it in 18 quarters since. The position peaked at $43.1K in Q3 2024. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Byrne Asset Management held 22 shares of Regeneron Pharmaceuticals worth $13.7K as of Q2 2026.
Byrne Asset Management left its Regeneron Pharmaceuticals share count unchanged in Q2 2026.
Regeneron Pharmaceuticals made up 0.01% of Byrne Asset Management's portfolio in Q2 2026, its #398 holding.
Byrne Asset Management first reported a position in Regeneron Pharmaceuticals in Q4 2021 and has held it in 18 quarters since.
Byrne Asset Management's Regeneron Pharmaceuticals position peaked at $43.1K in Q3 2024.
1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Byrne Asset Management's 13F filing for Q2 2026, filed 7 Jul 2026.